SCHEMBL4883514

SCHEMBL4883514

Cc1nc2ccc(NS(=O)(=O)c3ccc(Cl)cc3Cl)cc2o1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 3/20 0.53
LMNA P02545 4/20 0.50
MAPT P10636 4/20 0.50
TP53 P04637 3/20 0.50
POLB P06746 3/20 0.50
ITGA1 P56199 3/20 0.49
EDNRA P25101 2/20 0.49
PPARG P37231 5/20 0.48
CYP3A4 P08684 2/20 0.47
EDNRB P24530 1/20 0.47
MEN1 O00255 1/20 0.47
ALOX12 P18054 1/20 0.47
KMT2A Q03164 1/20 0.47
NLRP1 Q9C000 1/20 0.47
CDK1 P06493 1/20 0.47
CCNB1 P14635 1/20 0.47
CCNA2 P20248 1/20 0.47
CDK2 P24941 1/20 0.47
CDK7 P50613 1/20 0.47
CCNH P51946 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4881258 0.91 PTPN2 (0.55) FBP1ITGA1EDNRAPPARGCYP3A4
SCHEMBL617755 0.91 FBP1 (0.65) FBP1LMNAMAPTTP53POLB
SCHEMBL3037113 0.83 MAPT (0.56) LMNAMAPTTP53POLBCYP3A4
SCHEMBL618169 0.82 HSD11B1 (0.51) FBP1LMNAMAPTTP53POLB
SCHEMBL616005 0.81 FBP1 (0.65) FBP1MAPTTP53CDK1CCNB1
SCHEMBL4883530 0.76 LMNA (0.61) LMNAMAPTPOLBPPARGMEN1
SCHEMBL16325537 0.75 CDK1 (0.65) LMNAMAPTITGA1EDNRAPPARG
SCHEMBL2056293 0.74 PIK3CG (0.61) FBP1LMNAMAPTPOLB
SCHEMBL27422029 0.74 MEN1 (0.56) FBP1LMNAMAPTTP53MEN1
SCHEMBL4875632 0.74 LMNA (0.64) LMNAMAPTTP53POLBITGA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255169-A1 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread BIOTIE THERAPIES CORPORATION (FI) 2008-10-16 US disclosed
WO-2005090297-A1 SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255169-A1 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread NR1I2, ITGA2, ITGB2 FBP1 797/4885LMNA 3369/4885MAPT 4739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.